W1M Asset Management Ltd Invests $408.01 Million in Thermo Fisher Scientific Inc. $TMO

W1M Asset Management Ltd bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 814,886 shares of the medical research company’s stock, valued at approximately $408,009,000. Thermo Fisher Scientific accounts for 3.7% of W1M Asset Management Ltd’s holdings, making the stock its 11th biggest position. W1M Asset Management Ltd owned 0.22% of Thermo Fisher Scientific as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. High Note Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth about $25,000. Legacy Wealth Managment LLC ID boosted its holdings in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the last quarter. Finally, Birchwood Financial Partners Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price on the stock. Wolfe Research began coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target for the company. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Finally, Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $629.02 on Friday. The firm has a fifty day moving average of $542.53 and a 200-day moving average of $509.70. The company has a market cap of $232.58 billion, a price-to-earnings ratio of 33.84, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the firm posted $4.28 earnings per share. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This represents a 1.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 63,493 shares of company stock valued at $37,657,681. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.